Serna Bio Introduces Scientific Advisory Board to Advance RNA Drug Discovery
Serna Bio, a leading innovator in AI-driven drug discovery, has announced the formation of its Scientific Advisory Board (SAB), which brings together some of the most accomplished minds in RNA biology and drug development. This milestone strengthens Serna Bio’s efforts to develop next-generation small molecule therapies aimed at addressing diseases with limited or no treatment options.
Founded in 2021, Serna Bio specializes in preclinical drug discovery with its primary focus on neuro metabolism and obesity. The company’s groundbreaking platform is backed by esteemed investors including Y Combinator, Hummingbird Ventures, and 50Years. The SAB will play a pivotal role in accelerating Serna Bio’s mission to design innovative therapies by combining expertise in RNA biology, machine learning, and drug commercialization.
Revolutionary Approach to RNA-Targeting Small Molecules
“We have established a unique platform to discover a novel class of small molecules known as translational enhancers. These molecules are designed to target genetically validated mechanisms, offering new hope for treating diseases that currently lack effective therapies,” said Dr. Khan, MBA, PhD, founder and CEO of Serna Bio. “The strength of our intellectual property and platform has allowed us to collaborate with world-class experts who will amplify our efforts as we progress our lead assets toward clinical development.”
Dr. Khan emphasized the importance of the SAB members in shaping the company’s strategy and scientific direction. These advisors will utilize their deep expertise to guide Serna Bio in addressing critical challenges in disease treatment through RNA-targeting innovations.
Meet the Distinguished Members of Serna Bio’s SAB
The advisory board includes renowned academics and industry professionals, each bringing decades of experience in their respective fields:
- Dr. Nahum Sonenberg: A James McGill professor of biochemistry at McGill University, recognized for his groundbreaking work in translation initiation and the discovery of the mRNA 5′ cap-binding protein, eIF4E.
- Dr. Matthew Hayes: A leading expert in obesity drug discovery and neuroendocrine systems, Dr. Hayes serves as Vice Chair for Basic and Translational Neuroscience Research at the University of Pennsylvania.
- Dr. Jay Schneekloth: A senior investigator at the National Cancer Institute, Dr. Schneekloth specializes in RNA-small molecule interactions and has pioneered selective RNA-binding compounds.
- Giorgio Massimini: Former Vice President at Merck KGaA, with over 30 years of leadership in clinical research and the development of innovative therapies.
- Nick France: Vice President and Global Therapeutic Area Head for Genomic Medicines at Alexion, an expert in rare disease drug development.
- Jeff Ajer: Former Chief Commercial Officer at BioMarin, with a prolific career in commercializing therapies for rare diseases.
- Emily Freeman: Senior Director at Gilead Sciences, Freeman brings extensive experience in patient-focused implementation science and evidence-based communication strategies.
Driving Innovation in Translational Medicine
The SAB is set to guide Serna Bio in developing therapies that enhance translational processes at the molecular level. By leveraging its library of next-generation RNA-targeting small molecules, the company aims to address a wide array of diseases caused by insufficient protein expression.
Dr. Giorgio Massimini praised the company’s approach, stating, “Serna Bio’s unique platform targeting RNA has the potential to transform the treatment landscape for patients with unmet medical needs.” Similarly, Dr. Nick France highlighted the company’s commitment to providing solutions for rare genetic diseases, calling it a “game-changing mechanism of action.”
This announcement aligns with broader industry trends in leveraging machine learning and artificial intelligence to revolutionize drug discovery. For instance, the UK’s AI Strategy emphasizes the importance of integrating AI into healthcare to drive innovation and improve patient outcomes.
A Vision for the Future
With its SAB in place, Serna Bio is well-positioned to lead advancements in RNA-targeted therapies. By combining cutting-edge science with the strategic insights of its advisors, the company is paving the way for treatments that could significantly improve the lives of patients suffering from previously intractable diseases.
Serna Bio’s journey is a testament to the power of collaboration and innovation in addressing the most pressing challenges in healthcare. As the company moves forward, it remains committed to leveraging its expertise to create groundbreaking solutions in drug discovery.